Related Experiment Videos
Dopamine transporter SPECT in patients with mitochondrial disorders
M Minnerop1, C Kornblum, A Y Joe
1Department of Neurology, University of Bonn, Sigmund-Freud-Strasse 25, Bonn 53105, Germany.
Journal of Neurology, Neurosurgery, and Psychiatry
|December 21, 2004
Summary
Mitochondrial complex I deficiency does not appear to cause dopaminergic cell loss in Parkinson's disease. This study found no significant differences in dopamine transporter density in patients with this deficiency.
Area of Science:
- Neuroscience
- Mitochondrial Biology
- Neurology
Background:
- Mitochondrial disorders can impact basal ganglia function.
- Complex I deficiency in mitochondria is implicated in Parkinson's disease pathogenesis.
- Dopaminergic neuron loss is a hallmark of Parkinson's disease.
Purpose of the Study:
- To investigate the dopaminergic system in patients with mitochondrial disorders.
- To assess the role of complex I deficiency in dopaminergic dysfunction.
Main Methods:
- Utilized SPECT imaging with (123)I-FP-CIT to measure dopamine transporter density.
- Studied 10 female patients diagnosed with mitochondrial complex I deficiency.
Main Results:
- No significant differences in striatal binding ratios of (123)I-FP-CIT were observed.
- No correlation was found between the severity of complex I deficiency and striatal binding ratios.
Conclusions:
- Mitochondrial complex I deficiency alone is unlikely to cause dopaminergic cell loss.
- The findings suggest other factors contribute to dopaminergic neurodegeneration in Parkinson's disease.